Please use this identifier to cite or link to this item: http://sgc.anlis.gob.ar/handle/123456789/616
Title: Protocol for the Production of a Vaccine Against Argentinian Hemorrhagic Fever
Authors: Ambrosio, Ana María 
Mariani, Mauricio Andrés 
Maiza, Andrea Soledad 
Gamboa, Graciela Susana 
Fossa, Sebastián Edgardo 
Bottale, Alejando Javier 
Keywords: Fiebre Hemorrágica Americana;Arenaviridae;Argentina;Junín
Issue Date: 2018
Journal: Methods in molecular biology (Clifton, N.J.) 
Abstract: Argentinian hemorrhagic Fever (AHF) is a febrile, acute disease caused by Junín virus (JUNV), a member of the Arenaviridae. Different approaches to obtain an effective antigen to prevent AHF using complete live or inactivated virus, as well as molecular constructs, have reached diverse development stages. This chapter refers to JUNV live attenuated vaccine strain Candid #1, currently used in Argentina to prevent AHF. A general standardized protocol used at Instituto Nacional de Enfermedades Virales Humanas (Pergamino, Pcia. Buenos Aires, Argentina) to manufacture the tissue culture derived Candid #1 vaccine is described. Intermediate stages like viral seeds and cell culture bank management, bulk vaccine manufacture, and finished product processing are also separately presented in terms of Production and Quality Control/Quality Assurance requirements, under the Adminitracion Nacional de Medicamentos, Alimentos y Tecnología Medica (ANMAT), the Argentine national regulatory authority.
Description: Argentinian hemorrhagic Fever (AHF) is a febrile, acute disease caused by Junín virus (JUNV), a member of the Arenaviridae. Different approaches to obtain an effective antigen to prevent AHF using complete live or inactivated virus, as well as molecular constructs, have reached diverse development stages. This chapter refers to JUNV live attenuated vaccine strain Candid #1, currently used in Argentina to prevent AHF. A general standardized protocol used at Instituto Nacional de Enfermedades Virales Humanas (Pergamino, Pcia. Buenos Aires, Argentina) to manufacture the tissue culture derived Candid #1 vaccine is described. Intermediate stages like viral seeds and cell culture bank management, bulk vaccine manufacture, and finished product processing are also separately presented in terms of Production and Quality Control/Quality Assurance requirements, under the Adminitracion Nacional de Medicamentos, Alimentos y Tecnología Medica (ANMAT), the Argentine national regulatory authority.
URI: http://sgc.anlis.gob.ar/handle/123456789/616
DOI: 10.1007/978-1-4939-6981-4_24
Appears in Collections:Publicaciones INEVH

Show full item record

Page view(s)

4
checked on Sep 19, 2019

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.